文献速递临床试验与 GCP

N-乙酰半胱氨酸对系统性红斑狼疮疾病活动度及其相关并发症的影响:一项随机双盲临床试验研究

Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study.
PubMed 文献 · Trials · 2023-02-21

这项随机双盲临床试验纳入80例系统性红斑狼疮患者,40例接受N-乙酰半胱氨酸1800 mg/日治疗3个月,40例对照组接受常规治疗。结果显示NAC组BILAG和SLEDAI评分较基线及对照组均显著降低,多个器官系统并发症评分下降,CH50水平较基线升高,未报告不良事件。

要点

  • NAC组治疗3个月后BILAG评分较基线显著降低(P=0.023),SLEDAI评分较基线显著降低(P=0.034)。
  • 治疗3个月后NAC组BILAG评分显著低于对照组(P=0.021),SLEDAI评分显著低于对照组(P=0.030)。
  • NAC组治疗后BILAG总体及皮肤黏膜、神经、肌肉骨骼、心肺、肾脏、血管系统并发症评分较基线显著降低,CH50较基线显著升高(P=0.049),未报告不良事件。

核心结论

  • 作者认为,给予系统性红斑狼疮患者N-乙酰半胱氨酸1800 mg/日可降低疾病活动度及其并发症。

研究设计与样本

  • 随机双盲临床试验,纳入80例系统性红斑狼疮患者,分为NAC组40例(1800 mg/日,每日3次,间隔8小时,治疗3个月)和对照组40例(接受常规治疗)。
  • 治疗开始前和研究时间结束后测定实验室指标,并采用英国狼疮评估组(BILAG)和SLE疾病活动指数(SLEDAI)评估疾病活动度。

主要发现

  • NAC组治疗3个月后BILAG评分较基线显著降低(P=0.023),SLEDAI评分较基线显著降低(P=0.034)。
  • 治疗3个月后NAC组BILAG评分显著低于对照组(P=0.021),SLEDAI评分显著低于对照组(P=0.030)。
  • NAC组治疗后基于BILAG评分的各器官疾病活动度较基线显著降低:总体(P=0.018)、皮肤黏膜(P=0.003)、神经(P=0.015)、肌肉骨骼(P=0.048)、心肺(P=0.047)、肾脏(P=0.025)、血管(P=0.048)。
  • NAC组治疗后CH50水平较基线显著升高(P=0.049)。
  • 研究受试者未报告不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUNDS: N-acetylcysteine (NAC) has broadly been used as an anti-oxidant agent in various types of diseases. This study aimed to assess the effect of NAC on the systemic lupus erythematosus (SLE) disease activity and outcome. METHODS: In this randomized, double-blind clinical trial study, 80 SLE patients were recruited that were classified into two groups: 40 patients received NAC (1800 mg/day; 3 times per day with 8-h intervals) for 3 months and 40 patients as the control group received normal therapies. Laboratory measurements and disease activity based on the British Isles Lupus Assessment Group (BILAG) and SLE Disease Activity Index (SLEDAI) were determined before the initiation of treatment and after the study time period. RESULTS: A statistically significant decrease in BILAG (P= 0.023) and SLEDAI (P= 0.034) scores after receiving NAC for a 3-month period was observed. BILAG (P= 0.021) and SLEDAI (P= 0.030) scores were significantly lower in NAC-receiving patients compared to the control group after 3 months. The disease activity in each organ based on BILAG score after treatment indicated a significant decrease in the NAC group compared to the baseline level in general (P=0.018), mucocutaneous (P=0.003), neurological (P=0.015), musculoskeletal (P=0.048), cardiorespiratory (P=0.047), renal (P=0.025), and vascular (P=0.048) complications. Analysis indicated a significant increase in CH50 level in the NAC group after treatment compared to the baseline level (P=0.049). No adverse event was reported by the study subjects. CONCLUSIONS: It appears that the administration of 1800 mg/day NAC to SLE patients can decrease the SLE disease activity and its complications.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Abbasifard M, Khorramdelazad H, Rostamian A, et al. Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study. Trials. 2023. PMID: 36810107. doi:10.1186/s13063-023-07083-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。